Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$20.45 +1.9%	$17.91	$13.53 ▼ $35.25	$2.06B	2.07	1.57 million shs	2.00 million shs
CRSP CRISPR Therapeutics	$55.09 -0.1%	$43.70	$30.04 ▼ $63.39	$4.76B	1.82	1.96 million shs	2.17 million shs
DNLI Denali Therapeutics	$14.53 -2.3%	$14.24	$10.57 ▼ $33.33	$2.11B	1.33	1.15 million shs	1.03 million shs
EDIT Editas Medicine	$2.73 -3.9%	$2.06	$0.91 ▼ $5.91	$228.53M	2.15	2.64 million shs	1.83 million shs

Ten Starter Stocks For Beginners to Buy Now

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	+2.50%	-6.48%	+20.76%	+18.06%	-26.46%
CRSP CRISPR Therapeutics	+4.57%	-8.22%	+32.61%	+45.99%	-12.13%
DNLI Denali Therapeutics	+4.94%	-0.87%	+1.71%	+16.72%	-37.89%
EDIT Editas Medicine	+3.27%	-7.79%	+31.48%	+121.01%	-52.35%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	2.081 of 5 stars	3.5	0.0	0.0	2.5	2.5	0.6
CRSP CRISPR Therapeutics	3.264 of 5 stars	4.3	1.0	0.0	3.3	2.5	0.6
DNLI Denali Therapeutics	4.6841 of 5 stars	4.5	1.0	4.7	3.9	3.3	0.0
EDIT Editas Medicine	4.2479 of 5 stars	3.2	2.0	4.3	3.7	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$48.75	138.39% Upside
CRSP CRISPR Therapeutics	2.53	Moderate Buy	$71.75	30.24% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.71	132.03% Upside
EDIT Editas Medicine	2.31	Hold	$4.70	72.16% Upside

Current Analyst Ratings Breakdown

Latest BEAM, CRSP, DNLI, and EDIT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/8/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/27/2025	CRSP CRISPR Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$105.00
6/27/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00
6/27/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00
6/26/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00
6/26/2025	CRSP CRISPR Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$82.00
5/21/2025	CRSP CRISPR Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$86.00 ➝ $86.00
5/20/2025	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$81.00 ➝ $81.00
5/20/2025	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$65.00 ➝ $65.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/13/2025	EDIT Editas Medicine	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$8.00 ➝ $4.00

(Data available from 7/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	32.37	N/A	N/A	$8.86 per share	2.31
CRSP CRISPR Therapeutics	$37.31M	127.51	N/A	N/A	$22.64 per share	2.43
DNLI Denali Therapeutics	$330.53M	6.39	N/A	N/A	$8.53 per share	1.70
EDIT Editas Medicine	$32.31M	7.07	N/A	N/A	$1.63 per share	1.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
CRSP CRISPR Therapeutics	-$366.25M	-$4.52	N/A	N/A	N/A	-1,023.64%	-20.08%	-17.13%	8/4/2025 (Estimated)
DNLI Denali Therapeutics	-$422.77M	-$2.67	N/A	N/A	N/A	N/A	-35.90%	-32.41%	7/30/2025 (Estimated)
EDIT Editas Medicine	-$237.09M	-$3.04	N/A	N/A	N/A	-701.06%	-139.24%	-63.87%	8/6/2025 (Estimated)

Latest BEAM, CRSP, DNLI, and EDIT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	DNLI Denali Therapeutics	-$0.73	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	EDIT Editas Medicine	-$0.40	N/A	N/A	N/A	$1.81 million	N/A
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	N/A	N/A	N/A	$13.29 million	N/A
8/4/2025	Q2 2025	CRSP CRISPR Therapeutics	-$1.54	N/A	N/A	N/A	$6.44 million	N/A
5/12/2025	Q1 2025	EDIT Editas Medicine	-$0.51	-$0.43	+$0.08	-$0.92	$0.79 million	$4.66 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
5/6/2025	Q1 2025	CRSP CRISPR Therapeutics	-$1.27	-$1.58	-$0.31	-$1.58	N/A	N/A
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	8.81	8.81
CRSP CRISPR Therapeutics	N/A	15.64	15.64
DNLI Denali Therapeutics	N/A	9.56	9.56
EDIT Editas Medicine	N/A	3.08	3.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
CRSP CRISPR Therapeutics	69.20%
DNLI Denali Therapeutics	92.92%
EDIT Editas Medicine	71.90%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	3.50%
CRSP CRISPR Therapeutics	4.30%
DNLI Denali Therapeutics	12.50%
EDIT Editas Medicine	2.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
CRSP CRISPR Therapeutics	460	86.36 million	82.65 million	Optionable
DNLI Denali Therapeutics	430	145.28 million	127.12 million	Optionable
EDIT Editas Medicine	230	83.71 million	81.96 million	Optionable

BEAM, CRSP, DNLI, and EDIT Headlines

Recent News About These Companies

New horizons in sickle cell disease treatment: Promising therapies on the way

July 17 at 9:19 AM | labiotech.euL

Brokerages Set Editas Medicine, Inc. (NASDAQ:EDIT) PT at $4.70

July 17 at 3:41 AM | americanbankingnews.com

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts

July 12, 2025 | marketbeat.com

Editas Surpasses Therapeutic Gene Editing Threshold in New Preclinical Data

July 3, 2025 | msn.com

Editas Medicine Inc EDIT Company Vitals - U.S. News

July 1, 2025 | money.usnews.com

Sickle Cell Disease Treatment Market Set for Robust Growth Through 2034, Driven by Recent Clinical Pipeline Developments | DelveInsight

July 1, 2025 | theglobeandmail.com

Wall Street Expects Editas Medicine to Soar 53%. Is It Time to Buy Now?

June 28, 2025 | fool.com

Editas Medicine (NASDAQ:EDIT) Upgraded by Wall Street Zen to Hold Rating

June 27, 2025 | marketbeat.com

Editas Medicine Inc. Annual Cash Flow Statement - MarketWatch

June 25, 2025 | marketwatch.com

Editas Medicine Inc.

June 25, 2025 | barrons.com

Gene editors steady despite latest leadership shake-up at FDA

June 20, 2025 | msn.com

Lilly-Verve deal sends gene editing stocks higher

June 17, 2025 | msn.com

Editas Medicine Is Great. Here's Why You Shouldn't Buy It.

June 17, 2025 | msn.com

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Recommendation of "Hold" from Brokerages

June 17, 2025 | marketbeat.com

Editas Medicine Reports Proprietary Targeted Lipid Nanoparticle Delivery in Non-Human Primates Enables In Vivo HBG1/2 Promoter Editing for Sickle Cell Disease and Beta Thalassemia at the European Hematology Association 2025 Congress in June

June 12, 2025 | globenewswire.com

RFK Jr. Just Supercharged These 2 Biotech Penny Stocks

June 11, 2025 | msn.com

Why Is Editas (EDIT) Up 40% Since Last Earnings Report?

June 11, 2025 | zacks.com

Editas Medicine, Inc. (NASDAQ:EDIT) CEO Sells $26,130.24 in Stock

June 5, 2025 | insidertrades.com

Editas Medicine Stockholders Approve Key Amendments

June 2, 2025 | tipranks.com

Editas Medicine, Cassava Sciences among healthcare stocks to join Russell Microcap; MNKD, OCGN to exit

May 28, 2025 | seekingalpha.com

1 Stock Down 97% That Could Double, According to Wall Street

May 25, 2025 | fool.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAM, CRSP, DNLI, and EDIT Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$20.45 +0.38 (+1.89%)

Closing price 04:00 PM Eastern

Extended Trading

$20.57 +0.12 (+0.59%)

As of 06:52 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$55.09 -0.05 (-0.09%)

Closing price 04:00 PM Eastern

Extended Trading

$56.29 +1.20 (+2.19%)

As of 07:15 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Denali Therapeutics NASDAQ:DNLI

$14.53 -0.34 (-2.29%)

Closing price 04:00 PM Eastern

Extended Trading

$14.40 -0.13 (-0.89%)

As of 07:04 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Editas Medicine NASDAQ:EDIT

$2.73 -0.11 (-3.87%)

Closing price 04:00 PM Eastern

Extended Trading

$2.71 -0.02 (-0.73%)

As of 07:08 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time